Molecule, O'Ryan Health and BlueSavant AI launch autism RNA study

By AI, Created 12:56 PM UTC, May 26, 2026, /AGP/ – Molecule Science Foundation, O’Ryan Health and BlueSavant AI have launched a research initiative to build a decentralized bulk RNA dataset for autism spectrum disorder. The project aims to collect home-based blood samples from children and use the data to improve early detection research and test BlueSavant AI’s model.

Why it matters: - The partnership is designed to generate one of the largest decentralized bulk RNA datasets for autism spectrum disorder. - The dataset could help researchers identify biological patterns tied to ASD and improve earlier, more accurate detection. - The study is also intended to serve as a model for research on other pediatric neurodevelopmental conditions.

What happened: - Molecule Science Foundation, O’Ryan Health and BlueSavant AI announced a new research initiative in Dover, Delaware. - The project will use O’Ryan Health’s Artemis Platform to collect minimally invasive blood samples from families at home. - BlueSavant AI will analyze bulk RNA expression data from the samples. - The study will enroll children with a confirmed ASD diagnosis and neurotypical children as a comparison group.

The details: - The project aims to produce about 200 RNA expression profiles. - Families will collect small-volume blood samples at home using safe, minimally invasive devices. - The samples will be processed into bulk RNA expression data for analysis. - BlueSavant AI will use the data to test its autism detection model on real-world samples. - Molecule’s legal and technical infrastructure will support a community-driven charitable fundraise for the research. - O’Ryan Health’s Artemis Platform is being used to scale decentralized pediatric blood collection. - The initiative marks the first use of Molecule’s Coin-to-Company legal framework for a philanthropic ASD research project. - Donors giving $25 will receive one CRASD community association token. - Higher giving levels come with additional tokens and community membership benefits. - CRASD tokens are digital community membership credentials deployed on the Ethereum distributed ledger by the CRASD Cell, O’Ryan Rare Disease Series LLC. - The tokens are donated to Molecule Science Foundation for distribution to donors as membership premiums. - CRASD tokens provide access to research updates, community events and advisory participation opportunities described in the CRASD Token Whitepaper at the CRASD Token Whitepaper. - Molecule Science Foundation says it is a Delaware nonprofit focused on decentralized biotechnology research and public science education through grants and Sponsored Research Agreements. - The foundation has applied for 501(c)(3) status.

Between the lines: - The collaboration combines three pieces that are usually separate: fundraising infrastructure, at-home sample collection and AI-based analysis. - The pitch is that moving sample collection into homes could reduce access barriers that have slowed autism research. - The donor-token structure links philanthropic support with community participation, which may help the project raise funds while building an engaged research community. - BlueSavant AI’s model is positioned to benefit from higher-quality transcriptomic data gathered in a real-world setting. - The companies frame the effort as a shift from late autism diagnosis toward earlier screening and longitudinal tracking.

What’s next: - The partners will recruit children and begin collecting home-based blood samples for the study. - Researchers will build the RNA dataset and analyze it for ASD-related biological patterns. - BlueSavant AI will evaluate its detection model against the new sample set. - Molecule Science Foundation says contributors can support the project through tax-deductible philanthropic donations, subject to law, at more information.

The bottom line: - The partnership aims to turn at-home blood collection and AI analysis into a scalable autism research pipeline with real-world diagnostic potential.